Zanidatamab (ZW25), a HER2-targeted Bispecific Antibody, in Combination with Chemotherapy (chemo) for HER2-positive Breast Cancer (BC): Results from a Phase 1 Trial (San Antonio Breast Cancer Symposium, December 8, 2021)
Zanidatamab (ZW25) in Combination with Evorpacept (ALX148) in Advanced Human Epidermal Growth Factor Receptor 2 (HER2)-expressing Cancers, Including Breast Cancer: a Phase 1b/2, Multicenter, Open-Label, Dose-Finding and Cohort-Expansion Study (ZWI-ZW25-204) (San Antonio Breast Cancer Symposium, December 8, 2021)
VIDEO: Phase 2 Study of Zanidatamab + Chemotherapy in First-line HER2-expressing Gastroesophageal Adenocarcinoma (GEA) (Presented by: Geoffrey Ku, MD; European Society of Medical Oncology Annual Congress, September 16, 2021)
Zymeworks Topoisomerase 1 Inhibitor ADC Platform: From Concept to Pipeline (PEGS Boston Conference, May 2-6)
TOPO1i ADC Platform: From Concept to Pipeline (12th Annual World ADC London, March 31, 2022)